CN107028881A - 具有可逆的连续及分散相的纳米乳液 - Google Patents
具有可逆的连续及分散相的纳米乳液 Download PDFInfo
- Publication number
- CN107028881A CN107028881A CN201610906152.7A CN201610906152A CN107028881A CN 107028881 A CN107028881 A CN 107028881A CN 201610906152 A CN201610906152 A CN 201610906152A CN 107028881 A CN107028881 A CN 107028881A
- Authority
- CN
- China
- Prior art keywords
- oil
- nanoemulsions
- grams
- weight
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 311
- 230000002441 reversible effect Effects 0.000 title abstract description 7
- 239000012071 phase Substances 0.000 claims abstract description 176
- 239000008346 aqueous phase Substances 0.000 claims abstract description 154
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000007864 aqueous solution Substances 0.000 claims abstract description 29
- 239000002562 thickening agent Substances 0.000 claims abstract description 26
- 239000003381 stabilizer Substances 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 22
- 239000004094 surface-active agent Substances 0.000 claims abstract description 22
- 239000002086 nanomaterial Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 254
- 235000019198 oils Nutrition 0.000 claims description 253
- -1 methyl sulphonyl Chemical group 0.000 claims description 65
- 239000000194 fatty acid Substances 0.000 claims description 37
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 36
- 229930195729 fatty acid Natural products 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- 239000003240 coconut oil Substances 0.000 claims description 23
- 235000019864 coconut oil Nutrition 0.000 claims description 23
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 20
- 235000021355 Stearic acid Nutrition 0.000 claims description 18
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 18
- 239000008117 stearic acid Substances 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 15
- 229920000136 polysorbate Polymers 0.000 claims description 15
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 13
- 235000019482 Palm oil Nutrition 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 239000002540 palm oil Substances 0.000 claims description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 229940088594 vitamin Drugs 0.000 claims description 11
- 239000011782 vitamin Substances 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 235000019197 fats Nutrition 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 8
- 239000005662 Paraffin oil Substances 0.000 claims description 8
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 8
- 229940086555 cyclomethicone Drugs 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000005456 glyceride group Chemical group 0.000 claims description 8
- 229940031439 squalene Drugs 0.000 claims description 8
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 7
- HHVIBTZHLRERCL-UHFFFAOYSA-N methylsulphonylmethane Natural products CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 7
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 6
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 239000010495 camellia oil Substances 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 6
- 239000010642 eucalyptus oil Substances 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 229940070765 laurate Drugs 0.000 claims description 6
- 235000019254 sodium formate Nutrition 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 5
- 229940044949 eucalyptus oil Drugs 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 4
- 235000008524 evening primrose extract Nutrition 0.000 claims description 4
- 239000010475 evening primrose oil Substances 0.000 claims description 4
- 229940089020 evening primrose oil Drugs 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims description 4
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 4
- 239000010668 rosemary oil Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 claims description 3
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 3
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 claims description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 235000019500 Grapefruit seed oil Nutrition 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 229920002367 Polyisobutene Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 239000004280 Sodium formate Substances 0.000 claims description 3
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001275 dimeticone Drugs 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- DTTVNCZEOYSFFF-UHFFFAOYSA-N ethoxyurea Chemical compound CCONC(N)=O DTTVNCZEOYSFFF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 125000005908 glyceryl ester group Chemical group 0.000 claims description 3
- 150000002337 glycosamines Chemical class 0.000 claims description 3
- 229940051250 hexylene glycol Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 claims description 3
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229940058206 rosemary oil Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002545 silicone oil Polymers 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000012502 diagnostic product Substances 0.000 claims description 2
- 238000004043 dyeing Methods 0.000 claims description 2
- 239000003845 household chemical Substances 0.000 claims description 2
- 229940127554 medical product Drugs 0.000 claims description 2
- 229940057874 phenyl trimethicone Drugs 0.000 claims description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 claims description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 229920000742 Cotton Polymers 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims 2
- 235000021302 avocado oil Nutrition 0.000 claims 2
- 239000008163 avocado oil Substances 0.000 claims 2
- 239000004359 castor oil Substances 0.000 claims 2
- 235000019438 castor oil Nutrition 0.000 claims 2
- 239000003292 glue Substances 0.000 claims 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 2
- 229940060184 oil ingredients Drugs 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229920001296 polysiloxane Polymers 0.000 claims 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 229960004274 stearic acid Drugs 0.000 claims 2
- 244000004281 Eucalyptus maculata Species 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 230000005660 hydrophilic surface Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 description 87
- 238000012360 testing method Methods 0.000 description 86
- 238000002360 preparation method Methods 0.000 description 76
- 239000000203 mixture Substances 0.000 description 49
- 238000003756 stirring Methods 0.000 description 38
- 230000002459 sustained effect Effects 0.000 description 37
- 239000007788 liquid Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 28
- 235000011076 sorbitan monostearate Nutrition 0.000 description 21
- 239000003643 water by type Substances 0.000 description 18
- 235000013877 carbamide Nutrition 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- 235000013871 bee wax Nutrition 0.000 description 12
- 150000003672 ureas Chemical class 0.000 description 11
- 239000008389 polyethoxylated castor oil Substances 0.000 description 10
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 9
- 241001508687 Mustela erminea Species 0.000 description 9
- 235000017471 coenzyme Q10 Nutrition 0.000 description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 150000003625 trehaloses Chemical class 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000008169 grapeseed oil Substances 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 4
- 229960002722 terbinafine Drugs 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical class OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 3
- 235000020195 rice milk Nutrition 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 240000008821 Menyanthes trifoliata Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 229960003344 climbazole Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 229940063190 flagyl Drugs 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 2
- 229960004880 tolnaftate Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000010148 water-pollination Effects 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 description 1
- PGSQGVDBMYSHGO-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1NC=CC1.C1=CC=CC=C1 Chemical class C(C1=CC=CC=C1)C=1NC=CC1.C1=CC=CC=C1 PGSQGVDBMYSHGO-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 244000165852 Eucalyptus citriodora Species 0.000 description 1
- 235000004722 Eucalyptus citriodora Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010065027 Propanediol Dehydratase Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000010632 citronella oil Substances 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 125000005473 octanoic acid group Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000005471 saturated fatty acid group Chemical group 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003421 squalenes Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940078465 vanillyl butyl ether Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/80—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D11/00—Inks
- C09D11/02—Printing inks
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/017—Mixtures of compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/54—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种具有可逆的连续及分散相的纳米乳液。该纳米乳液包括水相及油相,所述水相与所述油相的重量比为1∶40至100∶1。在该纳米乳液中,所述水相以纳米级小液滴形式分散于所述油相中或所述油相以纳米级小液滴形式分散于所述水相中。所述水相含有水或水溶液及水溶性有机纳米结构稳定剂。所述油相含有油或油溶液、有机凝胶增稠剂及HLB值大于8.0的亲水性表面活性剂。还公开一种用于制备上述纳米乳液的方法。
Description
背景技术
存在两种类型的纳米乳液,即,水包油(o/w)纳米乳液及油包水(w/o)纳米乳液。o/w纳米乳液具有连续水相及分散油相,而w/o纳米乳液具有连续油相及分散水相。
这两种类型的纳米乳液通过具有不同亲水性亲脂性平衡(HLB)值的乳化剂得以稳定。o/w纳米乳液通过HLB值为8至28的乳化剂得以稳定,且w/o分散液通过HLB值为3至6的乳化剂得以稳定。因此,其无法轻易地进行相互转化。
缺乏可易转化性可能会存在问题。当o/w纳米乳液的含水量降低时,其会发生崩解。同样,当w/o纳米乳液的含油量降低时,其会发生崩解。
因此,需要研发一种纳米乳液,其连续相及分散相可经该纳米乳液中所包含的同一乳化剂容易进行相互转化。
发明内容
本文公开了一种含有可逆的连续及分散相的纳米乳液。
本发明的纳米乳液包括水相及油相,水相与油相的重量比为1∶40至100∶1。在纳米乳液中,水相以纳米级小液滴形式(作为纳米尺寸的液滴,nanosized droplet)分散于油相中或油相以纳米级小液滴形式分散于水相中。占纳米乳液的2.5重量%以上的水相含有水或水溶液及水溶性有机纳米结构稳定剂。按水相的重量计,水或水溶液的含量小于75%,且按水相的重量计,水溶性有机纳米结构稳定剂的含量小于99%。油相含有油或油溶液、有机凝胶增稠剂及HLB值大于8.0的亲水性表面活性剂。按油相的重量计,油或油溶液的含量小于80%,按油相的重量计,有机凝胶增稠剂的含量小于60%,且按油相的重量计,亲水性表面活性剂的含量小于60%。此纳米乳液可用作化妆品、食品或医药组合物中的活性成分的载体。
用于制备上述纳米乳液的方法也在本发明的范围内。该方法包括以下步骤:(1)将水或水溶液与水溶性有机纳米结构稳定剂混合以形成水相,其中按水相的重量计,水或水溶液的含量小于75%,且按水相的重量计,水溶性有机纳米结构稳定剂的含量小于99%;(2)将油或油溶液、有机增稠剂及亲水性亲脂性平衡值大于8.0的亲水性表面活性剂混合以形成油相,其中按油相的重量计,油或油溶液的含量小于80%,按油相的重量计,有机凝胶增稠剂的含量小于60%,且按油相的重量计,亲水性表面活性剂的含量小于60%;及(3)将水相与油相混合以形成纳米乳液,水相与油相的重量比为1∶40至100∶1,其中水或水溶液占纳米乳液的74重量%以下。在适合温度,例如,5℃至95℃下,进行混合步骤中的每一个。
在由此制得的纳米乳液中,水相以纳米级小液滴形式分散于油相中或油相以纳米级小液滴形式分散于水相中。换言之,纳米乳液中的连续及分散相为可逆的。
一个或多个实施例的细节阐述于以下描述中。实施例的其他特征、目的及优点将由说明书与权利要求书变得显而易见。
具体实施方式
本发明至少部分基于一项意外发现,即含有HLB值大于8的亲水性表面活性剂的纳米乳液可具有以纳米级小液滴形式分散于油相中的水相或以纳米级小液滴形式分散于水相中的油相。换言之,纳米乳液具有可逆的连续及分散相。
此纳米乳液可带有油溶性活性成分及水溶性活性成分,其为优于现有纳米乳液的优点。该优点在制备化妆品、食品、家用化学品、农业用产品、印刷产品、染色产品、兽医用产品、诊断产品、疫苗及医药产品方面尤其至关重要,如以下两个实例所说明。
o/w分散液优选用于化妆品中,因为相较于w/o分散液,其较不具有粘性及油脂性且具有期望的持水能力。然而,当将化妆品涂覆至皮肤或暴露于空气时,化妆品中的纳米乳液会经由蒸发而损失水。水损失会导致现有o/w纳米乳液崩解,而本发明的o/w纳米乳液则不会。取而代之,后一纳米乳液会缓慢转化成w/o纳米乳液,其中其水相以纳米级小液滴形式均匀地分散于其油相中。
不同地,对于油溶性药物,优选使用w/o分散液,归因于其负载量高。然而,当w/o纳米乳液开始与体液接触时,由于体液为含水的,其含水量必然会有所增加。因此,现有w/o纳米乳液会发生崩解。而本发明的w/o纳米乳液会缓慢转化成o/w纳米乳液,其中其油相以纳米级小液滴形式均匀地分散于其水相中。值得注意的是,转化不仅会维持纳米乳液的完整性且也会提供其中的药物的持续释放。
如上文所指出,本发明的纳米乳液包括水相及油相。在纳米乳液中,水相可以纳米级小液滴形式分散于油相中。或者,油相可以纳米级小液滴形式分散于水相中。
水相包括水溶性有机纳米结构稳定剂。术语“水溶性有机纳米结构稳定剂”在本文中是指可使纳米乳液的各向同性结构稳定,由此产生热力学上稳定的透明或半透明纳米乳液的任何水溶性有机成分。其可为水溶性维生素、水溶性肽、水溶性寡肽、多元醇、水溶性糖、水溶性寡糖、二糖、单糖、氢化碳水化合物、氨基酸、氨基糖或其组合。特定实例包括脲、甲基磺酰基甲烷、羟乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麦芽糖醇、异麦芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基二甘醇、肉毒碱、精氨酸、吡咯烷酮甲酸钠及水解胶原蛋白。
油相含有油或油溶液。可使用植物油、有机硅油、合成油、矿物油、动物油、精油或其组合来形成油相。特定实例包括椰子油、棕榈油、葡萄籽油、橄榄油、柚子油、亚麻籽油、鳄梨油、月见草油(evening primrose oil)、熏衣草油、迷迭香油、茶树油、桉树油、马脂、鱼油、羊毛脂油、角鲨烯(squalene)、环甲硅油(cyclomethicone)、环戊硅氧烷、苯基三甲基聚硅氧烷、辛酸/癸酸三甘油酯、肉豆蔻酸异丙酯、异硬脂酸异硬脂基酯、油酸癸酯、异壬酸乙基己酯、异十六烷、辛基十二醇、石蜡油、聚癸烯、聚异丁烯、薄荷醇或其组合。应注意,油溶液含有一种或多种作为用于溶解一种或多种油溶性溶质的溶剂的油。
也如上文所指出,油相包括HLB值大于8.0的亲水性表面活性剂。优选地,亲水性表面活性剂的HLB值大于10,且更优选地,HLB值大于13。亲水性表面活性剂的实例包括聚氧乙烯脱水山梨糖醇脂肪酸酯(Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween 81、Tween 85)、聚氧乙烯山梨糖醇脂肪酸酯、聚氧乙烯酸酯脂肪酸酯(Myri 45、Myri52、Myri 53、Myri 59)、聚氧乙烯酸脂肪酸酯(Myri 45、Myri 52、Myri 53、Myri 59)、聚氧伸乙基醇酯(Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij 99)、壬基苯酚烷氧基化物(WitconolTM基于壬基苯酚的非离子表面活性剂)、烷基烷氧基化物(EthylanTM家族非离子表面活性剂)、Pluronic F-127、PEG二甲硅油、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)糖脂肪酸酯、PEG-15甘油脂肪酸酯、PEG-35氢化蓖麻油、PEG-40氢化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其组合。
此外,油相含有有机凝胶增稠剂。术语“有机凝胶增稠剂”在本文中是指提高粘度且引起纳米乳液结构性形成的任何物质。有机凝胶增稠剂可为饱和脂肪酸、脂肪酸醇、熔点大于45℃的脂肪酸衍生物或其组合。有机凝胶增稠剂的实例包括硬脂酸、月桂酸、甘油单硬脂酸酯、PEG 6000 Diesterate、单甘油酯、二甘油酯、糖脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、抗坏血酸脂肪酸酯、甘油脂肪酸酯、脂肪酸己基癸酯或其组合。
在一个实施例中,按水相的重量计,本发明的纳米乳液的水或水溶液的含量小于60%,且按水相的重量计,水溶性有机纳米结构稳定剂的含量小于70%;按油相的重量计,油或油溶液的含量为30%至70%,按油相的重量计,有机凝胶增稠剂的含量小于45%,且按油相的重量计,亲水性表面活性剂的含量小于45%;且水或水溶液占纳米乳液的38重量%以下,且水相与油相的重量比为1∶3至4∶1。优选地,按水相的重量计,水或水溶液的含量小于45%,且按水相的重量计,水溶性有机纳米结构稳定剂的含量小于50%;按油相的重量计,油或油溶液的含量小于45%至65%,按油相的重量计,有机凝胶增稠剂的含量小于25%,且按油相的重量计,亲水性表面活性剂的含量小于35%;且水或水溶液占纳米乳液的30重量%以下,且水相与油相的重量比为1∶2至3∶1。
本发明的纳米乳液为透明或半透明的,其在3至11的pH下呈固态凝胶形式或液态形式。此外,其展现纳米特征,即,廷得尔光折射效应(Tyndall light refractioneffect)。参见Gold and Silver Nanoparticles,Center for Nanoscale Chemical-Electrical-Mechanical Manufacturing Systems,University of Illinois,http://Nano-cemms.illinois.edu/media/content/teaching_mats/online/gold_and_silver_nanoparticles/docs/presentation.pdf。
水或水溶液占纳米乳液的38重量%以下的本发明的纳米乳液具有自身防腐能力,且因此不需要在其中包括抗微生物防腐剂。防腐剂通常会引发安全性问题,因为其可能会造成介于轻度头痛至最严重疾病,例如癌症范围内的健康危害。
当用于化妆品、食品及医药组合物中时,此纳米乳液可带有各种活性成分,例如,特比萘芬(terbinafine)、双氯芬酸二乙胺、辣椒碱(capsaicin)、安定(diazepam)、劳拉西泮(lorazepam)、异丙酚、甲硝哒唑、吲哚美辛(indomethacine)、克霉唑、酮康唑、红霉素、甘宝素、活动素、联苯苄唑、咪康唑、托萘酯、氯倍他索、益康唑、胺苯甲酸乙酯、苯妥英(phenytoin)、洛伐他汀(lovastatin)、异山梨醇二硝酸酯、硝化甘油、法莫替丁(farmotidine)、没药醇、叶黄素酯、抑黑素、油溶性维生素、西红柿红素、白藜芦醇(resveratrol)、人参皂苷(ginsenoiside)、香草基丁基醚、姜黄素及CoQ10。可经由各种途径,例如,口服、局部、阴道、经直肠、舌下、肺部及非经肠来投与包括药物的纳米乳液。如果需要,也可添加某些甜味剂、调味剂、着色剂或芳香剂。
用于制备上述纳米乳液的本发明的方法包括首先分别形成水相及油相,且随后将两种相混合。可通过持续搅拌(手动或以其他方式)、高速及高剪切混合(例如,使用胶体研磨机)、高压混合(例如,使用微流化剂)或音波处理混合来混合水或水溶液及水溶性有机纳米结构稳定剂以形成水相。油或油溶液、有机增稠剂及亲水性表面活性剂也可由此混合而形成油相。所得水相及油相可随后以类似方式混合而形成纳米乳液。值得注意的是,如果需要,可在高温,例如45℃至85℃下进行全部混合步骤。重要的是,由此获得的油相及水相可用于制备o/w纳米乳液或w/o纳米乳液,其表明连续及分散相为可逆的。
在不进一步详细描述的情况下,据信以上描述已充分实现本发明。因此,以下实施例应理解为仅为说明性的且无论如何不以任何方式限制本发明的其余部分。本文中所引用的出版物以全文引用的方式并入本文中。
实施例1:纳米乳液类型的测定
将60ml水置放于100-ml烧杯中。将待测试的纳米乳液逐滴添加至水中。如果分散于水中的纳米乳液产生透明或半透明溶液,则所测试的纳米乳液为o/w纳米乳液。然而,如果纳米乳液在水中形成油状小液滴,则所测试的纳米乳液为w/o纳米乳液。实施例2:椰子油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合210克纯化水、90克脲、60克木糖醇、60克海藻糖及30克甲基磺酰基甲烷的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合80克椰子油、20克石蜡油、50克环甲硅油(DC-345)、20克蜂蜡、10克单硬脂酸甘油酯、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、36克聚乙二醇脱水山梨糖醇单硬脂酸酯及42克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
在65℃至75℃下通过在200-ml烧杯中持续手动搅拌来混合下表1中所示的重量比的上文所制备的油相及水相的组合持续低于0.5小时以形成w/o或o/w纳米乳液。
表1
ID | 1 | 2 | 3 | 4 |
油相(g) | 120 | 90 | 40 | 25 |
水相(g) | 30 | 60 | 60 | 75 |
纳米乳液(g) | 150 | 150 | 100 | 100 |
类型 | w/o | w/o | o/w | o/w |
物理外观 | 半透明 | 透明 | 透明 | 透明 |
全部纳米乳液在室温下稳定至少3个月且展现廷得尔(Tyndall)光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例3:棕榈油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
遵照实施例2中所述的程序制备由30克水相及120克油相组成的150克w/o纳米乳液,不同的处在于使用棕榈油代替椰子油。由此制备的纳米乳液为半透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液,不同的处在于使用棕榈油代替椰子油。由此制备的纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克o/w纳米乳液,不同之处在于使用棕榈油代替椰子油。由此制备的纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例2中所述的程序制备由75克水相及25克油相组成的100克o/w纳米乳液,不同之处在于使用棕榈油代替椰子油。由此制备的纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
此实施例中所制备的全部纳米乳液均通过遵照USP 35<51>,抗微生物有效性测试(Antimicrobial Effectiveness Testing),第52页中所述的程序进行的抗微生物测试。
实施例4:马脂纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液,不同之处在于使用马脂代替椰子油。
遵照实施例2中所述的程序制备由60克水相及40克油相组成的100克o/w纳米乳液,不同之处在于使用马脂代替椰子油。
由此制备的纳米乳液为透明的且在室温下稳定至少3个月。其均展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
实施例5:马脂纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克甘露糖醇的组合以形成水相。
纳米乳液的油相的制备
遵照实施例2中所述的程序制备油相,不同之处在于使用马脂代替椰子油。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由60克水相及40克油相组成的100克o/w纳米乳液。
由此制备的纳米乳液为透明的且在室温下稳定至少3个月。其均展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
实施例6:仅含有一种亲水性表面活性剂的棕榈油/角鲨烯纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
通过在置放于65℃至75℃下的500-ml烧杯中持续手动搅拌来混合180克纯化水、100克脲、20克丁二醇的组合以形成水相。纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合100克棕榈油、20克角鲨烯、25克环甲硅油(DC-345)、10克蜂蜡、20克硬脂酸、16克脱水山梨糖醇单硬脂酸酯及60克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合下表2中所示的重量比的上文所制备的油相及水相的组合至多0.5小时以形成也列于表2中的纳米乳液。
表2
ID | 1 | 2 | 3 | 4 |
油相(g) | 105 | 90 | 60 | 30 |
水相(g) | 15 | 60 | 90 | 120 |
总重量(g) | 120 | 150 | 150 | 150 |
类型 | w/o | w/o | o/w | o/w |
物理外观 | 半透明 | 透明 | 透明 | 透明 |
全部以上纳米乳液在室温下稳定至少3个月且展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例7:基于椰子油的医药纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
遵照实施例2中所述的程序制备由29.5克水相、溶解有0.5克油溶性医药活性成分的20克油相组成的50克o/w纳米乳液。油溶性医药活性成分为特比萘芬、双氯芬酸二乙胺、二乙胺、甲硝哒唑、吲哚美辛、克霉唑或红霉素。
由此制备的六种纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例8:基于棕榈油的医药纳米乳液的制备
遵照实施例7中所述的程序制备纳米乳液,不同的处在于使用棕榈油代替椰子油,且油溶性医药活性成分为特比萘芬、双氯芬酸二乙胺、甲康唑(metroconazole)、活动素、联苯苄唑及咪康唑。
由此制备的六种纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例9:含有甘宝素的精油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合40克茶树油、20克桉树油、30克薄荷醇、50克石蜡油、50克环甲硅油(DC-345)、20克蜂蜡、10克单硬脂酸甘油酯、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、36克聚乙二醇脱水山梨糖醇单硬脂酸酯及42克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及60克油相组成的150克o/w纳米乳液。
遵照实施例2中所述的程序制备由溶解有1克甘宝素的59克水相及40克油相组成的100克o/w纳米乳液。
全部以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例10:具有与实施例9中的水相不同的水相的精油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合210克纯化水、90克脲、60克木糖醇、60克海藻糖及30克甲基磺酰基甲烷的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合40克茶树油、20克桉树油、30克薄荷醇、50克石蜡油、50克环甲硅油(DC-345)、20克蜂蜡、10克单硬脂酸甘油酯、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、36克聚乙二醇脱水山梨糖醇单硬脂酸酯及42克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及60克油相组成的150克o/w纳米乳液。
两种纳米乳液为透明的且在室温下稳定至少3个月。其均展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
实施例11:含有托萘酯或酮康唑的精油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合50克茶树油、20克桉树油、15克薄荷醇、15克水杨酸甲酯、50克环甲硅油(DC-345)、10克蜂蜡、10克月桂酸、6克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、40克聚氧乙烯二醇(40)硬脂酸酯及40克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及60克油相组成的150克o/w纳米乳液。
遵照实施例2中所述的程序制备由60克水相及溶解有1.8克托萘酯的88.2克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由60克水相及溶解有1.8克酮康唑的88.2克油相组成的150克w/o纳米乳液。
全部以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例12:芳香剂/精油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合80克柠檬桉树油、40克香茅油、24克熏衣草油、22克桉树油、15克迷迭香油、15克樟脑、15克薄荷醇、6克百里香、10克蜂蜡、10克月桂酸、6克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、40克聚氧乙烯二醇(40)硬脂酸酯及40克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由60克水相及40克油相组成的100克o/w纳米乳液。
两种纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
实施例13:含有CoQ10的中长链油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、100克甘油、80克木糖醇、20克甘露糖醇及30克甲基磺酰基甲烷的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合170克中长链三酸甘油酯油、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、30克聚乙二醇脱水山梨糖醇单硬脂酸酯及30克PEG-40氢化蓖麻的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由50克水相及溶解有5克CoQ10的95克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及溶解有3克CoQ10的57克油相组成的150克o/w纳米乳液。
遵照实施例2中所述的程序制备由120克水相及溶解有3克CoQ10的30克油相组成的153克o/w纳米乳液。全部以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例14:中长链三酸甘油酯纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合100克纯化水、100克甘油、50克木糖醇、50克海藻糖、30克赤藻糖醇及15克麦芽糊精的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合170克中长链三酸甘油酯、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、30克聚乙二醇脱水山梨糖醇单硬脂酸酯及30克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由54克水相及溶解有6克叶黄素的120克油相组成的180克w/o纳米乳液。
遵照实施例2中所述的程序制备由174克水相及溶解有6克叶黄素的120克油相组成的300克o/w纳米乳液。
纳米乳液均为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
实施例15:含有CoQ10的中长链三酸甘油酯油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合100克纯化水、100克甘油、50克木糖醇、50克海藻糖、35克赤藻糖醇及15克麦芽糊精的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合50克中长链三酸甘油酯、50克鱼油、10克硬脂酸、8克脱水山梨糖醇单硬脂酸酯、20克聚乙二醇脱水山梨糖醇单硬脂酸酯及20克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由20克水相及溶解有5克CoQ10的100克油相组成的125克w/o纳米乳液。
遵照实施例2中所述的程序制备由58克水相及溶解有2克CoQ10的40克油相组成的100克o/w纳米乳液。
纳米乳液均为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例16:含有异山梨醇二硝酸酯或法莫替丁的角鲨烯/辛酸癸酸三甘油酯纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合80克角鲨烯、80克辛酸癸酸三甘油酯、16克硬脂酸、14克脱水山梨糖醇单硬脂酸酯、40克聚氧乙烯二醇(40)硬脂酸酯及40克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及60克油组成的150克o/w纳米乳液。
遵照实施例2中所述的程序制备由88.5克水相及溶解有1.5克异山梨醇二硝酸酯的60克油相组成的150克o/w纳米乳液。
遵照实施例2中所述的程序制备由88.5克水相及溶解有1.5克法莫替丁的60克油相组成的150克o/w纳米乳液。
全部以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例17:含有姜黄素或睪固酮的合成油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合80克辛酸癸酸三甘油酯、40克油酸乙酯、40克脱水山梨糖醇油酸酯、8克蜂蜡、8克月桂酸、8克脱水山梨糖醇单硬脂酸酯及64克聚氧乙烯二醇(40)硬脂酸酯的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由45克水相及90克油相组成的135克w/o纳米乳液。
遵照实施例2中所述的程序制备由45克水相及溶解有1.8克睪固酮的88.2克油相组成的135克w/o纳米乳液。
遵照实施例2中所述的程序制备由45克水相及溶解有0.6克姜黄素的89.4克油相组成的135克w/o纳米乳液。
全部以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的全部纳米乳液均通过此抗微生物测试。
实施例18:含有CoQ10、维生素A、维生素E及维生素D的纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合280克纯化水、240克甘油、48克脲及32克海藻糖的组合以形成600克水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合2.4克CoQ10、4.8克维生素A、1.2克维生素D 1.2、30克维生素E、85.6克石蜡油、140克环甲硅油(DC-345)、32克硬脂酸、24克脱水山梨糖醇硬脂酸酯及80克聚乙二醇脱水山梨糖醇单硬脂酸酯的组合以形成400克油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由600克水相及400克油相组成的1000克纳米乳液。
以上纳米乳液为透明o/w纳米乳液且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序测定纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(AntimicrobialEffectivenessTesting),第52页中所述的程序进行抗微生物测试,且纳米乳液通过此抗微生物测试。
实施例19:维生素E/葡萄籽油/椰子油/貂油/石蜡油/环甲硅油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合168克纯化水、115克脲、77克甘油、20克丙二醇、20克吡咯烷酮甲酸钠及20克海藻糖的组合以形成420克水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合30克维生素E、30克葡萄籽油、40克椰子油、8克貂油、24克石蜡油、60克环甲硅油(DC-345)、16克蜂蜡、8克单硬脂酸甘油酯、19克硬脂酸、17克脱水山梨糖醇单硬脂酸酯、50克PEG-40氢化蓖麻油及28克聚氧乙烯二醇(40)硬脂酸酯的组合以形成330克油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由420克水相及330克油相组成的750克纳米乳液。
以上纳米乳液为透明o/w纳米乳液且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序测定纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且纳米乳液通过此抗微生物测试。
实施例20:维生素E/葡萄籽油/椰子油/貂油/石蜡油/环甲硅油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合168克纯化水、115克脲、77克甘油、20克丙二醇、20克吡咯烷酮甲酸钠及20克海藻糖的组合以形成420克水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合30克维生素E、30克葡萄籽油、40克椰子油、8克貂油、24克石蜡油、60克环甲硅油(DC-345)、16克蜂蜡、8克单硬脂酸甘油酯、19克硬脂酸、17克脱水山梨糖醇单硬脂酸酯、50克PEG-40氢化蓖麻油及28克聚乙二醇脱水山梨糖醇单硬脂酸酯的组合以形成330克油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由420克水相及330克油相组成的750克纳米乳液。
以上纳米乳液为透明o/w纳米乳液且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序测定纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且纳米乳液通过此抗微生物测试。
实施例21:维生素E/葡萄籽油/椰子油/貂油/石蜡油/环甲硅油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合168克纯化水、115克脲、77克甘油、20克丙二醇、20克吡咯烷酮甲酸钠及20克海藻糖的组合以形成420克水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合30克维生素E、30克葡萄籽油、40克椰子油、8克貂油、24克石蜡油、60克环甲硅油(DC-345)、16克蜂蜡、8克单硬脂酸甘油酯、19克硬脂酸、17克脱水山梨糖醇单硬脂酸酯、50克PEG-40氢化蓖麻油及28克聚氧乙烯脱水山梨糖醇单油酸酯的组合以形成330克油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由420克水相及330克油相组成的750克纳米乳液。
以上纳米乳液为透明o/w纳米乳液且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序测定纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且纳米乳液通过此抗微生物测试。
实施例22:维生素E/葡萄籽油/椰子油/貂油/石蜡油/环甲硅油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在烧杯中持续手动搅拌来混合150克纯化水、150克脲及40克丙二醇的组合以形成340克水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合30克维生素E、30克葡萄籽油、40克椰子油、8克貂油、24克石蜡油、60克环甲硅油(DC-345)、16克蜂蜡、8克单硬脂酸甘油酯、19克硬脂酸、17克脱水山梨糖醇单硬脂酸酯、50克PEG-40氢化蓖麻油及28克聚氧乙烯二醇(40)硬脂酸酯的组合以形成330克油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由420克水相及330克油相组成的750克纳米乳液。
以上纳米乳液为透明o/w纳米乳液且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序测定纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且纳米乳液通过此抗微生物测试。
实施例23:仅含一种亲水性表面活性剂的精油纳米乳液的制备
遵照如下所述的程序制备纳米乳液。
纳米乳液的水相的制备
在65℃至75℃下通过在500-ml烧杯中持续手动搅拌来混合200克纯化水、100克甘油、50克葡糖胺及50克甲基磺酰基甲烷的组合以形成水相。
纳米乳液的油相的制备
在65℃至75℃下通过在400-ml烧杯中持续手动搅拌来混合30克维生素E、30克葡萄籽油、40克椰子油、8克貂油、24克石蜡油、60克环甲硅油(DC-345)、16克蜂蜡、8克单硬脂酸甘油酯、19克硬脂酸、17克脱水山梨糖醇单硬脂酸酯及68克PEG-40氢化蓖麻油的组合以形成油相。
纳米乳液的制备
遵照实施例2中所述的程序制备由60克水相及90克油相组成的150克w/o纳米乳液。
遵照实施例2中所述的程序制备由90克水相及60克油相组成的150克o/w纳米乳液。
以上纳米乳液为透明的且在室温下稳定至少3个月。其展现廷得尔光折射效应。
遵照实施例1中所述的程序来测定此实施例中所制备的各纳米乳液的类型。
遵照USP 35<51>,抗微生物有效性测试(Antimicrobial EffectivenessTesting),第52页中所述的程序进行抗微生物测试,且此实施例中所制备的两种纳米乳液均通过此抗微生物测试。
其他实施例
本说明书中公开的所有特征可以任何组合形式组合。本说明书中公开的各特征可经用于相同、等效或类似目的的替代性特征置换。因此,除非另外明确说明,否则所公开的各特征仅为一系列等效或类似通用特征的一个实施例。
根据以上描述,本领域技术人员可易于确定本发明的基本特征,且在不脱离本发明的精神及范围的情况下可对本发明作出各种改变及修改以使其适应各种用途及条件。因此,其他实施例也处于以下权利要求书的范围内。
Claims (23)
1.一种纳米乳液,其包含:
(A)水相,其包括:
(1)水或水溶液,及
(2)水溶性有机纳米结构稳定剂,
其中按所述水相的重量计,所述水或水溶液的含量小于75%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于99%,和
(B)油相,其包括:
(1)油或油溶液,
(2)有机凝胶增稠剂,及
(3)亲水性亲脂性平衡值大于8.0的亲水性表面活性剂,
其中按所述油相的重量计,所述油或油溶液的含量小于80%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于60%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于60%,
其中所述水或水溶液占所述纳米乳液的2.5重量%以上,所述水相与所述油相的重量比为1∶40至100∶1,并且所述水相以纳米级小液滴形式分散于所述油相中或所述油相以纳米级小液滴形式分散于所述水相中。
2.如权利要求1的纳米乳液,其中所述油相以纳米级小液滴形式分散于所述水相中。
3.如权利要求1的纳米乳液,其中所述水相以纳米级小液滴形式分散于所述油相中。
4.如权利要求2的纳米乳液,其中所述亲水性亲脂性平衡值大于10。
5.如权利要求4的纳米乳液,其中所述亲水性亲脂性平衡值大于13。
6.如权利要求3的纳米乳液,其中所述亲水性亲脂性平衡值大于10。
7.如权利要求6的纳米乳液,其中所述亲水性亲脂性平衡值大于13。
8.如权利要求4的纳米乳液,其中所述水溶性有机纳米结构稳定剂为水溶性维生素、水溶性肽、水溶性寡肽、多元醇、水溶性糖、水溶性寡糖、二糖、单糖、氢化碳水化合物、氨基酸、氨基糖或其组合;所述油为植物油、有机硅油、合成油、矿物油、动物油、精油或其组合;并且所述有机凝胶增稠剂为饱和脂肪酸、脂肪酸醇、熔点大于45℃的脂肪酸衍生物或其组合。
9.如权利要求4的纳米乳液,其中所述水溶性有机纳米结构稳定剂为脲、甲基磺酰基甲烷、羟乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麦芽糖醇、异麦芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基二甘醇、肉毒碱、精氨酸、吡咯烷酮甲酸钠及水解胶原蛋白或其组合;所述油为椰子油、棕榈油、葡萄籽油、柚子油、橄榄油、鳄梨油、月见草油、茶树油、桉树油、熏衣草油、迷迭香油、马脂、鱼油、角鲨烯、羊毛脂油、角鲨烯、环甲硅油、环戊硅氧烷、苯基三甲基聚硅氧烷、辛酸/癸酸三甘油酯、肉豆蔻酸异丙酯、异硬脂酸异硬脂基酯、油酸癸酯、异壬酸乙基己酯、异十六烷、辛基十二醇、石蜡油、聚异丁烯、聚癸烯、薄荷醇或其组合;所述有机凝胶增稠剂为硬脂酸、月桂酸、甘油单硬脂酸酯、PEG6000Diesterate、单甘油酯、二甘油酯、糖脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、抗坏血酸脂肪酸酯、甘油脂肪酸酯、脂肪酸己基癸酯或其组合;并且所述亲水性表面活性剂包括Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween81、Tween 85、Myri 45、Myri 52、Myri 53、Myri 59、Myri 45、Myri 52、Myri 53、Myri 59、Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij99、壬基苯酚烷氧基化物、烷基烷氧基化物、Pluronic F-127、PEG二甲硅油、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)糖脂肪酸酯、PEG-15甘油脂肪酸酯、PEG-35氢化蓖麻油、PEG-40氢化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其组合。
10.如权利要求9的纳米乳液,其中所述亲水性亲脂性平衡值大于13;按所述水相的重量计,所述水或水溶液的含量小于60%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于50%;按所述油相的重量计,所述油或油溶液的含量小于45%至65%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于25%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于35%;所述水或水溶液占所述纳米乳液的30重量%以下,并且所述水相与所述油相的重量比为1∶2至3∶1;并且所述纳米乳液的pH为3至11且为透明或半透明的。
11.如权利要求6的纳米乳液,其中所述水溶性有机纳米结构稳定剂为水溶性维生素、水溶性肽、水溶性寡肽、多元醇、水溶性糖、水溶性寡糖、二糖、单糖、氢化碳水化合物、氨基酸、氨基糖或其组合;所述油为植物油、有机硅油、合成油、矿物油、动物油、精油或其组合;并且所述有机凝胶增稠剂为饱和脂肪酸、脂肪酸醇、熔点大于45℃的脂肪酸衍生物或其组合。
12.如权利要求4的纳米乳液,其中所述水溶性有机纳米结构稳定剂为脲、甲基磺酰基甲烷、羟乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麦芽糖醇、异麦芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基二甘醇、肉毒碱、精氨酸、吡咯烷酮甲酸钠及水解胶原蛋白或其组合;所述油为椰子油、棕榈油、葡萄籽油、柚子油、橄榄油、鳄梨油、月见草油、茶树油、桉树油、熏衣草油、迷迭香油、马脂、鱼油、角鲨烯、羊毛脂油、角鲨烯、环甲硅油、环戊硅氧烷、苯基三甲基聚硅氧烷、辛酸/癸酸三甘油酯、肉豆蔻酸异丙酯、异硬脂酸异硬脂基酯、油酸癸酯、异壬酸乙基己酯、异十六烷、辛基十二醇、石蜡油、聚异丁烯、聚癸烯、薄荷醇或其组合;所述有机凝胶增稠剂为硬脂酸、月桂酸、甘油单硬脂酸酯、PEG 6000 Diesterate、单甘油酯、二甘油酯、糖脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、抗坏血酸脂肪酸酯、甘油脂肪酸酯、脂肪酸己基癸酯或其组合;并且所述亲水性表面活性剂包括Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween81、Tween 85、Myri 45、Myri 52、Myri 53、Myri 59、Myri 45、Myri 52、Myri 53、Myri 59、Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij99、壬基苯酚烷氧基化物、烷基烷氧基化物、Pluronic F-127、PEG二甲硅油、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)糖脂肪酸酯、PEG-15甘油脂肪酸酯、PEG-35氢化蓖麻油、PEG-40氢化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其组合。
13.如权利要求12的纳米乳液,其中所述亲水性亲脂性平衡值大于13;按所述水相的重量计,所述水或水溶液的含量小于60%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于50%;按所述油相的重量计,所述油或油溶液的含量小于45%至65%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于25%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于35%;所述水或水溶液占所述纳米乳液的30重量%以下,并且所述水相与所述油相的重量比为1∶2至3∶1;并且所述纳米乳液的pH为3至11且为透明或半透明的。
14.如权利要求8的纳米乳液,其中按所述水相的重量计,所述水或水溶液的含量小于60%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于70%;按所述油相的重量计,所述油或油溶液的含量为30%至70%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于45%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于45%;并且所述水或水溶液占所述纳米乳液的38重量%以下,并且所述水相与所述油相的重量比为1∶3至4∶1。
15.如权利要求14的纳米乳液,其中按所述水相的重量计,所述水或水溶液的含量小于45%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于50%;按所述油相的重量计,所述油或油溶液的含量小于45%至65%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于25%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于35%;并且所述水或水溶液占所述纳米乳液的30重量%以下,并且所述水相与所述油相的重量比为1∶2至3∶1。
16.如权利要求11的纳米乳液,其中按所述水相的重量计,所述水或水溶液的含量小于60%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于70%;按所述油相的重量计,所述油或油溶液的含量为30%至70%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于45%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于45%;并且所述水或水溶液占所述纳米乳液的38重量%以下,并且所述水相与所述油相的重量比为1∶3至4∶1。
17.如权利要求16的纳米乳液,其中按所述水相的重量计,所述水或水溶液的含量小于45%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于50%;按所述油相的重量计,所述油或油溶液的含量小于45%至65%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于25%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于35%;并且所述水或水溶液占所述纳米乳液的30重量%以下,并且所述水相与所述油相的重量比为1∶2至3∶1。
18.如权利要求15的纳米乳液,其中所述纳米乳液的pH为3至11且为透明或半透明的。
19.如权利要求17的纳米乳液,其中所述纳米乳液的pH为3至11且为透明或半透明的。
20.如权利要求1的纳米乳液,其中所述纳米乳液的pH为3至11且为透明或半透明的。
21.如权利要求1的纳米乳液,其中所述纳米乳液为自身防腐的。
22.如权利要求1的纳米乳液,其中所述纳米乳液为化妆品、医药产品、食品、家用化学品、农业用产品、印刷产品、染色产品、兽医用产品或诊断产品。
23.一种用于制备纳米乳液的方法,所述方法包括:
(1)将水或水溶液与水溶性有机纳米结构稳定剂混合以形成水相,其中按所述水相的重量计,所述水或水溶液的含量小于75%,并且按所述水相的重量计,所述水溶性有机纳米结构稳定剂的含量小于99%;
(2)将油或油溶液、有机增稠剂及亲水性亲脂性平衡值大于8.0的亲水性表面活性剂混合以形成油相,其中按所述油相的重量计,所述油或油溶液的含量小于80%,按所述油相的重量计,所述有机凝胶增稠剂的含量小于60%,并且按所述油相的重量计,所述亲水性表面活性剂的含量小于60%;和
(3)将所述水相与所述油相混合以形成纳米乳液,所述水相与所述油相的重量比为1∶40至100∶1,其中所述水或水溶液占所述纳米乳液的74重量%以下;
由此所述水相以纳米级小液滴形式分散于所述油相中或所述油相以纳米级小液滴形式分散于所述水相中。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/921,572 US9872832B2 (en) | 2015-10-23 | 2015-10-23 | Nanoemulsions having reversible continuous and dispersed phases |
US14/921,572 | 2015-10-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107028881A true CN107028881A (zh) | 2017-08-11 |
CN107028881B CN107028881B (zh) | 2021-08-17 |
Family
ID=57280963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610906152.7A Active CN107028881B (zh) | 2015-10-23 | 2016-10-18 | 具有可逆的连续及分散相的纳米乳液 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9872832B2 (zh) |
EP (1) | EP3159012B1 (zh) |
JP (1) | JP6266051B2 (zh) |
KR (1) | KR101884083B1 (zh) |
CN (1) | CN107028881B (zh) |
AR (1) | AR106403A1 (zh) |
CA (1) | CA2945444C (zh) |
DK (1) | DK3159012T3 (zh) |
ES (1) | ES2753751T3 (zh) |
MX (1) | MX2016013718A (zh) |
MY (1) | MY180028A (zh) |
PH (1) | PH12016000352A1 (zh) |
SG (1) | SG10201608533VA (zh) |
TW (1) | TWI769990B (zh) |
ZA (1) | ZA201606887B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107865778A (zh) * | 2017-11-13 | 2018-04-03 | 广州市花安堂生物科技有限公司 | 一种油凝胶组合物及其制备方法和应用 |
CN109662900A (zh) * | 2019-02-25 | 2019-04-23 | 南京华狮新材料有限公司 | 一种磷脂包裹纳米乳组合物及其制备方法和应用 |
CN109691682A (zh) * | 2019-02-22 | 2019-04-30 | 广西中烟工业有限责任公司 | 一种乳化角鲨烯分散液及其制备方法和烟草涂布液 |
CN111629705A (zh) * | 2018-01-23 | 2020-09-04 | 荷兰联合利华有限公司 | 包含月桂油的透明纳米乳液 |
CN111629706A (zh) * | 2018-01-23 | 2020-09-04 | 荷兰联合利华有限公司 | 用于制备包含月桂油的透明纳米乳液的方法 |
CN112165927A (zh) * | 2018-05-23 | 2021-01-01 | 荷兰联合利华有限公司 | 纳米乳液及其制备方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020502087A (ja) | 2016-12-21 | 2020-01-23 | ユニリーバー・ナームローゼ・ベンノートシヤープ | アミノ酸およびニコチンアミド化合物を含む外用皮膚美白添加物および組成物 |
WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
CN110121330B (zh) | 2016-12-21 | 2022-04-29 | 联合利华知识产权控股有限公司 | 具有包含4-取代的间苯二酚和氨基酸的谷胱甘肽前体的个人护理组合物 |
EA201991185A1 (ru) | 2016-12-21 | 2020-01-13 | Юнилевер Н.В. | Композиции для личной гигиены, содержащие цистин |
US20210000707A1 (en) * | 2017-07-12 | 2021-01-07 | Conopco, Inc., D/B/A Unilever | Nanoemulsions with color stabilized actives |
EP3694476B1 (en) * | 2017-10-10 | 2024-01-31 | Unilever IP Holdings B.V. | Nanoemulsions with neutralized fatty acid and a method producing the same |
US10959975B1 (en) | 2017-11-02 | 2021-03-30 | The Tetra Corporation | Antifungal composition, method of making composition, and method of using composition |
WO2019117378A1 (ko) * | 2017-12-15 | 2019-06-20 | 농업회사법인(주)제주우다 | 마유 또는 동백유를 함유하는 나노 에멀젼을 포함하는 화장료 조성물 |
KR102044908B1 (ko) * | 2017-12-27 | 2019-11-14 | 주식회사 메가코스 | 투명성이 개선된 고함량 천연 오일을 함유한 나노 에멀젼 조성물, 이를 포함하는 화장료 조성물 및 이의 제조 방법 |
KR102067094B1 (ko) * | 2018-04-17 | 2020-01-15 | 김철환 | 비(非)계면활성제형 오일-물(o/w) 분산 조성물, 비(非)계면활성제형 물-오일(w/o) 분산 조성물 및 이들의 제조방법 |
CA3098801C (en) | 2018-05-04 | 2024-04-09 | Johnson & Johnson Consumer Inc. | Cleansing composition comprising stearic esters |
US20220023193A1 (en) * | 2018-11-26 | 2022-01-27 | Colgate-Palmolive Company | Personal Care Compositions |
JP7298863B2 (ja) * | 2018-12-26 | 2023-06-27 | クラシエホームプロダクツ株式会社 | 乳化化粧料 |
US11813354B1 (en) * | 2019-01-11 | 2023-11-14 | Shear Kershman Laboratories, Inc | Trans-mucosal delivery system for testosterone |
US11465107B2 (en) * | 2019-01-31 | 2022-10-11 | Hong Ngoc Thi Dang | Process for producing a nano omega-3 microemulsion system |
CN113557002B (zh) | 2019-04-01 | 2023-11-24 | 联合利华知识产权控股有限公司 | 包含油连续纳米乳液的多重乳液及使用该乳液的方法 |
KR102258968B1 (ko) * | 2019-06-20 | 2021-05-31 | 건국대학교 산학협력단 | 오리 오일을 포함하는 나노에멀젼 및 이의 용도 |
CN112263542B (zh) * | 2020-10-19 | 2023-09-01 | 澳美制药厂有限公司 | 地奈德纳米乳凝胶组合物及其制备方法 |
KR102537101B1 (ko) | 2020-10-28 | 2023-05-30 | 주식회사 메가코스 | 스쿠알렌을 포함하는 나노 에멀젼 조성물, 이를 포함하는 화장료 조성물 및 이의 제조 방법 |
CN112891305B (zh) * | 2021-01-27 | 2022-03-08 | 深圳大学 | 利用不饱和古罗糖醛酸负载白藜芦醇的o/w型纳米乳的制备方法 |
KR102661960B1 (ko) * | 2023-09-07 | 2024-04-29 | 주식회사 뉴앤뉴 | 저 에너지 소요 나노 에멀젼의 제조방법 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018147A1 (en) * | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
CN1376046A (zh) * | 1999-09-24 | 2002-10-23 | 雷克特本克斯尔(英国)有限公司 | 皮肤处理组合物 |
WO2007094605A1 (en) * | 2006-02-14 | 2007-08-23 | Amorepacific Corporation | Topical preparation composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases |
EP2000130A1 (en) * | 1999-06-30 | 2008-12-10 | Lipocine, Inc. | Clear- oil-containing pharmaceutical compositions |
CN101664372A (zh) * | 2009-10-12 | 2010-03-10 | 董萍 | 一种皮肤外用抗氧化网络功效纳米乳及其制备方法 |
US20120052126A1 (en) * | 2010-08-30 | 2012-03-01 | Yashwant Pathak | Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds |
CN103690425A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型含柠檬精油亚微米乳液及其制备方法 |
CN103690379A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型乳木果油纳米乳液及其制备方法 |
CN104490661A (zh) * | 2014-12-04 | 2015-04-08 | 上海应用技术学院 | 一种含柠檬精油的o/w型纳米乳液及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0746331B1 (en) | 1992-10-16 | 2000-09-13 | IBAH, Inc. | Convertible microemulsion formulations |
US6214318B1 (en) * | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US7393548B2 (en) | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
JP2002273192A (ja) * | 2001-03-19 | 2002-09-24 | Yamagata Univ Research Institute | pHにより可逆的に転相する乳化組成物 |
US20080138296A1 (en) * | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7488471B2 (en) | 2002-10-28 | 2009-02-10 | Mmp, Inc. | Transparent oil-in-water emulsion |
US20060193813A1 (en) * | 2005-02-11 | 2006-08-31 | L'oreal | Nanoemulsion containing a hydroxylated urea compound |
FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
WO2009042166A1 (en) * | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
ATE526338T1 (de) * | 2008-04-14 | 2011-10-15 | Cognis Ip Man Gmbh | Alkyl- und/oder alkenylether von alkyl- und/oder alkenyl(poly)glycosiden und ihre verwendung |
-
2015
- 2015-10-23 US US14/921,572 patent/US9872832B2/en active Active
-
2016
- 2016-07-29 JP JP2016150503A patent/JP6266051B2/ja active Active
- 2016-10-04 PH PH12016000352A patent/PH12016000352A1/en unknown
- 2016-10-07 ZA ZA2016/06887A patent/ZA201606887B/en unknown
- 2016-10-12 SG SG10201608533VA patent/SG10201608533VA/en unknown
- 2016-10-17 CA CA2945444A patent/CA2945444C/en active Active
- 2016-10-18 CN CN201610906152.7A patent/CN107028881B/zh active Active
- 2016-10-19 MX MX2016013718A patent/MX2016013718A/es unknown
- 2016-10-19 AR ARP160103185A patent/AR106403A1/es unknown
- 2016-10-20 MY MYPI2016703856A patent/MY180028A/en unknown
- 2016-10-21 TW TW105134148A patent/TWI769990B/zh active
- 2016-10-21 EP EP16195013.4A patent/EP3159012B1/en active Active
- 2016-10-21 KR KR1020160137654A patent/KR101884083B1/ko active IP Right Grant
- 2016-10-21 ES ES16195013T patent/ES2753751T3/es active Active
- 2016-10-21 DK DK16195013T patent/DK3159012T3/da active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992018147A1 (en) * | 1991-04-19 | 1992-10-29 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
EP2000130A1 (en) * | 1999-06-30 | 2008-12-10 | Lipocine, Inc. | Clear- oil-containing pharmaceutical compositions |
CN1376046A (zh) * | 1999-09-24 | 2002-10-23 | 雷克特本克斯尔(英国)有限公司 | 皮肤处理组合物 |
WO2007094605A1 (en) * | 2006-02-14 | 2007-08-23 | Amorepacific Corporation | Topical preparation composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases |
CN101664372A (zh) * | 2009-10-12 | 2010-03-10 | 董萍 | 一种皮肤外用抗氧化网络功效纳米乳及其制备方法 |
US20120052126A1 (en) * | 2010-08-30 | 2012-03-01 | Yashwant Pathak | Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds |
CN103690425A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型含柠檬精油亚微米乳液及其制备方法 |
CN103690379A (zh) * | 2013-12-12 | 2014-04-02 | 上海应用技术学院 | 一种o/w型乳木果油纳米乳液及其制备方法 |
CN104490661A (zh) * | 2014-12-04 | 2015-04-08 | 上海应用技术学院 | 一种含柠檬精油的o/w型纳米乳液及其制备方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107865778A (zh) * | 2017-11-13 | 2018-04-03 | 广州市花安堂生物科技有限公司 | 一种油凝胶组合物及其制备方法和应用 |
CN111629705A (zh) * | 2018-01-23 | 2020-09-04 | 荷兰联合利华有限公司 | 包含月桂油的透明纳米乳液 |
CN111629706A (zh) * | 2018-01-23 | 2020-09-04 | 荷兰联合利华有限公司 | 用于制备包含月桂油的透明纳米乳液的方法 |
CN111629706B (zh) * | 2018-01-23 | 2023-05-16 | 联合利华知识产权控股有限公司 | 用于制备包含月桂油的透明纳米乳液的方法 |
CN112165927A (zh) * | 2018-05-23 | 2021-01-01 | 荷兰联合利华有限公司 | 纳米乳液及其制备方法 |
CN112165927B (zh) * | 2018-05-23 | 2024-01-30 | 联合利华知识产权控股有限公司 | 纳米乳液及其制备方法 |
CN109691682A (zh) * | 2019-02-22 | 2019-04-30 | 广西中烟工业有限责任公司 | 一种乳化角鲨烯分散液及其制备方法和烟草涂布液 |
CN109662900A (zh) * | 2019-02-25 | 2019-04-23 | 南京华狮新材料有限公司 | 一种磷脂包裹纳米乳组合物及其制备方法和应用 |
CN109662900B (zh) * | 2019-02-25 | 2022-03-22 | 南京华狮新材料有限公司 | 一种磷脂包裹纳米乳组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US20170112764A1 (en) | 2017-04-27 |
DK3159012T3 (da) | 2019-11-11 |
AR106403A1 (es) | 2018-01-10 |
MX2016013718A (es) | 2018-04-18 |
BR102016024625A2 (pt) | 2018-03-27 |
CA2945444C (en) | 2022-04-26 |
MY180028A (en) | 2020-11-20 |
KR101884083B1 (ko) | 2018-07-31 |
CN107028881B (zh) | 2021-08-17 |
SG10201608533VA (en) | 2017-05-30 |
KR20170048190A (ko) | 2017-05-08 |
CA2945444A1 (en) | 2017-04-23 |
TW201714605A (zh) | 2017-05-01 |
PH12016000352A1 (en) | 2018-04-11 |
TWI769990B (zh) | 2022-07-11 |
JP2017081896A (ja) | 2017-05-18 |
US9872832B2 (en) | 2018-01-23 |
ZA201606887B (en) | 2017-11-29 |
EP3159012B1 (en) | 2019-08-14 |
JP6266051B2 (ja) | 2018-01-24 |
EP3159012A1 (en) | 2017-04-26 |
ES2753751T3 (es) | 2020-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107028881A (zh) | 具有可逆的连续及分散相的纳米乳液 | |
Yang et al. | Encapsulating plant ingredients for dermocosmetic application: An updated review of delivery systems and characterization techniques | |
CN101583339B (zh) | 包含脂质和表面活性剂的大分子组装体的组合物 | |
CN101484121B (zh) | 大尺寸脂质囊乳剂组合物和含有它的化妆品组合物 | |
CN105934239A (zh) | 优选包含亲脂性活性剂的脂质微胶囊和包含它的组合物,它们的制备方法和它们在皮肤病学和化妆品中的用途 | |
TW200932282A (en) | Skin care preparation for external use | |
CN106619321A (zh) | 一种含有油性组分的面贴膜 | |
KR101633639B1 (ko) | 자기회합 겔 특성을 이용한 세포막 유사 구조의 나노 겔타입의 에멀젼 및 그를 이용한 화장료 조성물 | |
JP6339376B2 (ja) | 化粧料 | |
WO2016013772A1 (ko) | 다량의 유분을 포함하면서 피부개선효과가 우수한 하이드로겔 마스크의 제조방법 및 이를 통하여 제조된 하이드로겔 조성물 | |
CN106102708A (zh) | 神经酰胺分散组合物的制造方法 | |
JP5889220B2 (ja) | 水性分散組成物 | |
CN104203202B (zh) | 包含植物卵磷脂的发用化妆品组合物 | |
KR100732728B1 (ko) | 저점도의 에멀젼 화장료 조성물 | |
CN106061462B (zh) | 神经酰胺分散组合物 | |
JP2012036102A (ja) | 水中油型エマルション組成物およびエアゾール組成物 | |
KR102266174B1 (ko) | 나노셀룰로오스를 함유한 나노에멀젼 유화 조성물 및 이의 제조 방법 | |
WO2016182926A1 (en) | Preparation of nanoemulsions | |
CN105030569A (zh) | 分散组合物及化妆料 | |
JP2011001289A (ja) | 乳化液の製造方法及び化粧料の製造方法 | |
CN107592808A (zh) | 化妆品纳米乳液 | |
JP2017081848A (ja) | 水中油型皮膚外用剤 | |
AU2016247173B2 (en) | Nanoemulsions having reversible continuous and dispersed phases | |
CN109984958A (zh) | 水包油型乳化组合物及气溶胶化妆材料 | |
JP7497296B2 (ja) | ナノエマルジョン及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1235699 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |